Drugs that contain Lasmiditan Succinate

1. Reyvow patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7423050 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Feb, 2028

(3 years from now)

US11053214 ELI LILLY AND CO Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Dec, 2037

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459 ELI LILLY AND CO Pyridinoylpiperidines as 5-HT1F agonists
Mar, 2023

(1 year, 1 month ago)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 31, 2025

NCE-1 date: 01 February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine


More Information on Dosage

REYVOW family patents

Family Patents